Quantbot Technologies LP Takes $1.31 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Quantbot Technologies LP has acquired a new stake in ANI Pharmaceuticals, purchasing 19,585 shares valued at approximately $1.31 million. This investment represents a small ownership of 0.09% in the company.
• Insider trading activity includes significant sales by COO Muthusamy Shanmugam and CEO Nikhil Lalwani, with the two selling a combined total of over $9.5 million in stock recently.
• ANI Pharmaceuticals reported strong quarterly earnings with an EPS of $1.80, surpassing analysts’ expectations, and revenue growth of 53.2% year-over-year.

Quantbot Technologies LP purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,585 shares of the specialty pharmaceutical company's stock, valued at approximately $1,311,000. Quantbot Technologies LP owned 0.09% of ANI Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. National Bank of Canada FI acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $79,000. GAMMA Investing LLC increased its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares during the period. Mesirow Financial Investment Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $206,000. Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Finally, Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $204,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Buying and Selling

In other news, COO Muthusamy Shanmugam sold 52,990 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $87.15, for a total value of $4,618,078.50. Following the transaction, the chief operating officer owned 531,920 shares in the company, valued at $46,356,828. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 56,960 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total value of $4,894,572.80. Following the completion of the transaction, the chief executive officer owned 411,219 shares in the company, valued at $35,336,048.67. This represents a 12.17% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 401,247 shares of company stock valued at $35,300,435. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:ANIP opened at $91.01 on Friday. The business's 50 day simple moving average is $70.63 and its two-hundred day simple moving average is $65.91. The firm has a market cap of $1.97 billion, a P/E ratio of -118.19 and a beta of 0.61. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $92.53.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company's quarterly revenue was up 53.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 earnings per share. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Guggenheim restated a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial upped their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. HC Wainwright restated a "buy" rating and set a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Piper Sandler restated an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.